123 related articles for article (PubMed ID: 26553780)
1. Prospective Clinical Study of Precision Oncology in Solid Tumors.
Sohal DP; Rini BI; Khorana AA; Dreicer R; Abraham J; Procop GW; Saunthararajah Y; Pennell NA; Stevenson JP; Pelley R; Estfan B; Shepard D; Funchain P; Elson P; Adelstein DJ; Bolwell BJ
J Natl Cancer Inst; 2015 Nov; 108(3):. PubMed ID: 26553780
[TBL] [Abstract][Full Text] [Related]
2. Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer.
Keller RB; Mazor T; Sholl L; Aguirre AJ; Singh H; Sethi N; Bass A; Nagaraja AK; Brais LK; Hill E; Hennessey C; Cusick M; Del Vecchio Fitz C; Zwiesler Z; Siegel E; Ovalle A; Trukhanov P; Hansel J; Shapiro GI; Abrams TA; Biller LH; Chan JA; Cleary JM; Corsello SM; Enzinger AC; Enzinger PC; Mayer RJ; McCleary NJ; Meyerhardt JA; Ng K; Patel AK; Perez KJ; Rahma OE; Rubinson DA; Wisch JS; Yurgelun MB; Hassett MJ; MacConaill L; Schrag D; Cerami E; Wolpin BM; Nowak JA; Giannakis M
JCO Precis Oncol; 2023 Jan; 7():e2200342. PubMed ID: 36634297
[TBL] [Abstract][Full Text] [Related]
3. Precision Oncology in Pediatric Cancer Surgery.
Lee WG; Kim ES
Surg Oncol Clin N Am; 2024 Apr; 33(2):409-446. PubMed ID: 38401917
[TBL] [Abstract][Full Text] [Related]
4. The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies.
Murciano-Goroff YR; Drilon A; Stadler ZK
Cancer Cell; 2021 Jan; 39(1):22-24. PubMed ID: 33434511
[TBL] [Abstract][Full Text] [Related]
5. Precision Oncology in Hepatopancreatobiliary Cancer Surgery.
Newhook TE; Tsai S; Meric-Bernstam F
Surg Oncol Clin N Am; 2024 Apr; 33(2):343-367. PubMed ID: 38401914
[TBL] [Abstract][Full Text] [Related]
6. Direct-to-Patient Clinical Trials: One Small Step or a Giant Leap?
Desai A; Subbiah V
Clin Cancer Res; 2023 Jul; 29(13):2339-2341. PubMed ID: 37125861
[TBL] [Abstract][Full Text] [Related]
7. Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.
Hirshfield KM; Tolkunov D; Zhong H; Ali SM; Stein MN; Murphy S; Vig H; Vazquez A; Glod J; Moss RA; Belyi V; Chan CS; Chen S; Goodell L; Foran D; Yelensky R; Palma NA; Sun JX; Miller VA; Stephens PJ; Ross JS; Kaufman H; Poplin E; Mehnert J; Tan AR; Bertino JR; Aisner J; DiPaola RS; Rodriguez-Rodriguez L; Ganesan S
Oncologist; 2016 Nov; 21(11):1315-1325. PubMed ID: 27566247
[TBL] [Abstract][Full Text] [Related]
8. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.
Schwaederle M; Parker BA; Schwab RB; Daniels GA; Piccioni DE; Kesari S; Helsten TL; Bazhenova LA; Romero J; Fanta PT; Lippman SM; Kurzrock R
Mol Cancer Ther; 2016 Apr; 15(4):743-52. PubMed ID: 26873727
[TBL] [Abstract][Full Text] [Related]
9. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.
Blumenthal DT; Dvir A; Lossos A; Tzuk-Shina T; Lior T; Limon D; Yust-Katz S; Lokiec A; Ram Z; Ross JS; Ali SM; Yair R; Soussan-Gutman L; Bokstein F
J Neurooncol; 2016 Oct; 130(1):211-219. PubMed ID: 27531351
[TBL] [Abstract][Full Text] [Related]
11. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
Rodriguez-Rodriguez L; Hirshfield KM; Rojas V; DiPaola RS; Gibbon D; Hellmann M; Isani S; Leiser A; Riedlinger GM; Wagreich A; Ali SM; Elvin JA; Miller VA; Ganesan S
Gynecol Oncol; 2016 Apr; 141(1):2-9. PubMed ID: 27016222
[TBL] [Abstract][Full Text] [Related]
12. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.
Schwaederle M; Zhao M; Lee JJ; Lazar V; Leyland-Jones B; Schilsky RL; Mendelsohn J; Kurzrock R
JAMA Oncol; 2016 Nov; 2(11):1452-1459. PubMed ID: 27273579
[TBL] [Abstract][Full Text] [Related]
13. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
Johnson DB; Frampton GM; Rioth MJ; Yusko E; Xu Y; Guo X; Ennis RC; Fabrizio D; Chalmers ZR; Greenbowe J; Ali SM; Balasubramanian S; Sun JX; He Y; Frederick DT; Puzanov I; Balko JM; Cates JM; Ross JS; Sanders C; Robins H; Shyr Y; Miller VA; Stephens PJ; Sullivan RJ; Sosman JA; Lovly CM
Cancer Immunol Res; 2016 Nov; 4(11):959-967. PubMed ID: 27671167
[TBL] [Abstract][Full Text] [Related]
14. Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer.
Parsons HA; Beaver JA; Cimino-Mathews A; Ali SM; Axilbund J; Chu D; Connolly RM; Cochran RL; Croessmann S; Clark TA; Gocke CD; Jeter SC; Kennedy MR; Lauring J; Lee J; Lipson D; Miller VA; Otto GA; Rosner GL; Ross JS; Slater S; Stephens PJ; VanDenBerg DA; Wolff AC; Young LE; Zabransky DJ; Zhang Z; Zorzi J; Stearns V; Park BH
Clin Cancer Res; 2017 Jan; 23(2):379-386. PubMed ID: 27489289
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing.
Schrock AB; Frampton GM; Herndon D; Greenbowe JR; Wang K; Lipson D; Yelensky R; Chalmers ZR; Chmielecki J; Elvin JA; Wollner M; Dvir A; -Gutman LS; Bordoni R; Peled N; Braiteh F; Raez L; Erlich R; Ou SH; Mohamed M; Ross JS; Stephens PJ; Ali SM; Miller VA
Clin Cancer Res; 2016 Jul; 22(13):3281-5. PubMed ID: 26933124
[TBL] [Abstract][Full Text] [Related]
16. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Radovich M; Kiel PJ; Nance SM; Niland EE; Parsley ME; Ferguson ME; Jiang G; Ammakkanavar NR; Einhorn LH; Cheng L; Nassiri M; Davidson DD; Rushing DA; Loehrer PJ; Pili R; Hanna N; Callaghan JT; Skaar TC; Helft PR; Shahda S; O'Neil BH; Schneider BP
Oncotarget; 2016 Aug; 7(35):56491-56500. PubMed ID: 27447854
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
19. Biliary cancer: Utility of next-generation sequencing for clinical management.
Javle M; Bekaii-Saab T; Jain A; Wang Y; Kelley RK; Wang K; Kang HC; Catenacci D; Ali S; Krishnan S; Ahn D; Bocobo AG; Zuo M; Kaseb A; Miller V; Stephens PJ; Meric-Bernstam F; Shroff R; Ross J
Cancer; 2016 Dec; 122(24):3838-3847. PubMed ID: 27622582
[TBL] [Abstract][Full Text] [Related]
20. Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies.
Dhir M; Choudry HA; Holtzman MP; Pingpank JF; Ahrendt SA; Zureikat AH; Hogg ME; Bartlett DL; Zeh HJ; Singhi AD; Bahary N
Cancer Med; 2017 Jan; 6(1):195-206. PubMed ID: 28028924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]